Nexentis Technologies: N2OFF Rebrands to Focus on AI-Driven Biotech

Neve Yarak, Israel – February 25, 2026 – N2OFF, Inc. (NASDAQ: NITO) has announced a comprehensive corporate rebranding to Nexentis Technologies Inc. (“Nexentis”), effective February 26, 2026. The company’s Nasdaq trading symbol will change from “NITO” to “NXTS” on that date . This strategic shift reflects Nexentis’s evolution into an innovative, AI and data-driven computational biotechnology platform.

A New Focus on Mitochondrial Biology

The rebranding highlights Nexentis’s commitment to leveraging MITOLINE™ and mitochondrial carrier biology in the development of treatments for oncology and inflammatory metabolic diseases . A core component of this transformation is the integration and scaling of MitoCareX Bio Ltd. (“MitoCareX”), now a wholly-owned subsidiary of Nexentis.

MitoCareX and the MITOLINE™ Platform

MitoCareX brings a proprietary discovery engine to Nexentis, targeting the mitochondrial SLC25 carrier family. This engine utilizes the MITOLINE™ algorithm and structure-guided virtual screening workflows . Nexentis intends to use this platform to build a diversified pipeline of first-in-class small-molecule programs.

Strategic Acquisition and Pipeline Development

The rebranding follows the completion of N2OFF’s acquisition of MitoCareX on October 20, 2025 . MitoCareX focuses on drug discovery for resistant cancers and inflammatory metabolic disease indications. Initial results from MitoCareX’s research show that selected MITOLINE™-derived small molecule candidates reduced key inflammatory markers in human immune cells, suggesting the potential for anti-inflammatory effects through modulation of mitochondrial transporters .

Continued Investment in Renewable Energy

While prioritizing its biotech focus, Nexentis will continue to selectively manage its investments in renewable energy assets, specifically solar projects in Europe based on the Ready to Build (RTB) business model . The company currently holds investments in four solar projects across three European Union countries.

Other Investments

Nexentis also controls approximately 98% of Save Foods Ltd., an Israeli company specializing in post-harvest processing technologies to reduce pathogen contamination in fruits and vegetables .

Looking Ahead

The Nexentis brand is designed to embody the company’s focus on the “next” generation of mitochondrial medicines. The company’s charter amendment, approved by the board, will not affect shareholder rights or the stock’s CUSIP number .